Clinical trial · Interventional
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
NCT03511768CI-TRIAL-00032721unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to investigate the clinical value of \[18F\]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Neoplasm | Neuroendocrine Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-AlF-NOTA-octreotide | Drug | — | UNRESOLVED |
| PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-AlF-NOTA-octreotide PET/CT
- description
- One injection of the radioligand 18F-AlF-NOTA-octreotide
- interventionNames
- Drug: 18F-AlF-NOTA-octreotide
- Device: PET/CT
Primary outcomes (1)
- measure
- 18F-AlF-NOTA-octreotide PET/CT imaging of patients with Neuroendocrine Neoplasms
- timeFrame
- 12 months
- description
- The radioligand 18F-AlF-NOTA-octreotide can be used to visualize neuroendocrine neoplasms
Secondary outcomes (1)
- measure
- 18F-AlF-NOTA-octreotide PET/CT prognostic factor for overall and disease specific survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically and/or clinically confirmed and/or suspicious of NEN. 2. Signed informed consent. Exclusion Criteria: 1. Claustrophobia (unable to accept PET/CT scanning) 2. Pregnant or breast-feeding
References
Publications (1)
- RESULTLaverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, Goldenberg DM, Boerman OC. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med. 2010 Mar;51(3):454-61. doi: 10.2967/jnumed.109.066902. Epub 2010 Feb 11. PMID 20150268